Exact Mass: 503.15282160000004
Exact Mass Matches: 503.15282160000004
Found 140 metabolites which its exact mass value is equals to given mass value 503.15282160000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
[(2S,3S,4S)-4,6-Diamino-3-hydroxy-1-[[(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]amino]-1,6-dioxohexan-2-yl] dihydrogen phosphate
C20H30N3O10P (503.16687300000007)
Gravacridonediol glucoside
C25H29NO10 (503.17913740000006)
Gravacridonediol glucoside is found in herbs and spices. Gravacridonediol glucoside is an alkaloid from Ruta graveolens (rue
Pyranodelphinin B
Pyranodelphinin B is found in fruits. Pyranodelphinin B is a constituent of the seeds of Ribes nigrum (blackcurrant)
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose is a constituent of blood group substance of human milk. Constituent of blood group substance of human milk
(Z)-2-((R)-1-((S)-1-(2-Chlorophenyl)-2-methoxy-2-oxoethyl)-4-((2-(3-methoxyphenyl)-2-oxoethyl)thio)piperidin-3-ylidene)acetic acid
C25H26ClNO6S (503.1169286000001)
Naloxone-3-glucuronide
C25H29NO10 (503.17913740000006)
Sulfuric acid 2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazine-3-yl ester
C26H21N3O6S (503.11510060000006)
{(2R)-2-[alpha-D-glucopyranosyl(1->6)beta-D-glucopyranosyloxy]-2-(3-hydroxy-4-methoxyphenyl)}acetonitrile
C21H29NO13 (503.16388240000003)
Cys His Met Asn
Cys His Asn Met
Cys Met His Asn
Cys Met Asn His
Cys Asn His Met
Cys Asn Met His
Asp Asn Gln Gln
Asp Pro Ser Trp
Asp Pro Trp Ser
Asp Gln Asn Gln
Asp Gln Gln Asn
Asp Ser Pro Trp
Asp Ser Trp Pro
Asp Trp Pro Ser
Asp Trp Ser Pro
Glu Asn Asn Gln
Glu Asn Gln Asn
Glu Gln Asn Asn
His Cys Met Asn
His Cys Asn Met
His Met Cys Asn
His Met Asn Cys
His Asn Cys Met
His Asn Met Cys
Met Cys His Asn
Met Cys Asn His
Met His Cys Asn
Met His Asn Cys
Met Asn Cys His
Met Asn His Cys
Asn Cys His Met
Asn Cys Met His
Asn Asp Gln Gln
Asn Glu Asn Gln
Asn Glu Gln Asn
Asn His Cys Met
Asn His Met Cys
Asn Met Cys His
Asn Met His Cys
Asn Asn Glu Gln
Asn Asn Gln Glu
Asn Gln Asp Gln
Asn Gln Glu Asn
Asn Gln Asn Glu
Asn Gln Gln Asp
Pro Asp Ser Trp
Pro Asp Trp Ser
Pro Ser Asp Trp
Pro Ser Trp Asp
Pro Trp Asp Ser
Pro Trp Ser Asp
Gln Asp Asn Gln
Gln Asp Gln Asn
Gln Glu Asn Asn
Gln Asn Asp Gln
Gln Asn Glu Asn
Gln Asn Asn Glu
Gln Asn Gln Asp
Gln Gln Asp Asn
Gln Gln Asn Asp
Ser Asp Pro Trp
Ser Asp Trp Pro
Ser Pro Asp Trp
Ser Pro Trp Asp
Ser Trp Asp Pro
Ser Trp Pro Asp
Trp Asp Pro Ser
Trp Asp Ser Pro
Trp Pro Asp Ser
Trp Pro Ser Asp
Trp Ser Asp Pro
Trp Ser Pro Asp
Gravacridonediol glucoside
C25H29NO10 (503.17913740000006)
Pyranodelphinin B
beta-D-Galactopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->6)-D-mannose
Rosuvastatin calcium
C22H27FN3NaO6S (503.1502214000001)
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
2 3 5-TRI-O-BENZOYL-BETA-D-RIBOFURANOSYL
C27H21NO7S (503.10386760000006)
4-methoxyphenyl 4,6-o-benzylidene-2-deoxy-2-phthalimido-beta-d-glucopyranoside
1-Decyl-3-Methylimidazolium Bis(Trifluoromethylsulfonyl)Imide
5,5,5′,5′,5′′,5′′-Hexamethyltris(1,2,3-Dioxaphosphorinanemethan)-Amin 2,2′,2′′-Trioxid
((hydroxy((2-(6-pivalaMido-9H-purin-9-yl)ethoxy)Methyl)phosphoryl)oxy)Methyl pivalate
4-Methylphenyl 2-O-(phenylmethyl)-1-thio-beta-D-galactopyranoside triacetate
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
C26H20F3N7O (503.16813460000003)
3-(1h-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid
C28H29N3O4S (503.1878674000001)
[7-Methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3,4,5-trihydroxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-ylidene]oxidanium
3-L-arginyl-AMP
An L-arginyl ester obtained by formal condensation of the carboxy group of L-arginine with the 3-hydroxy group of AMP.
(1R)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
C23H29N5O6S (503.18384540000005)
2-[(2R,4aS,12aS)-8-(methanesulfonamido)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyphenyl)acetamide
C24H29N3O7S (503.17261240000005)
2-[(3S,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
C22H34ClN3O6S (503.1856734000001)
[(1S)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C25H30ClN3O4S (503.1645450000001)
2-[(3R,6aR,8S,10aR)-1-(4-chlorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide
C22H34ClN3O6S (503.1856734000001)
[(1R)-2-[(3-chlorophenyl)methyl]-1-ethylsulfonyl-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C25H30ClN3O4S (503.1645450000001)
(1S)-N-(3,5-dimethyl-4-isoxazolyl)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
C23H29N5O6S (503.18384540000005)
4-[7-[Ethyl(5-carboxypentyl)amino]-2-oxo-2H-1-benzopyran-3-yl]-1-(3-sulfonatopropyl)pyridinium
YH239-EE
C25H27Cl2N3O4 (503.13785220000005)
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets in four AML cells (OCI-AML-3 and MOLM-13 with wt p53, NB4 with p53 mutation, and HL60 with p53 deletion).
4-amino-3-hydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-2-(phosphonooxy)hexanediimidic acid
C20H30N3O10P (503.16687300000007)
(2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl)oxysulfonic acid
(2r)-2-(3-hydroxy-4-methoxyphenyl)-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}acetonitrile
C21H29NO13 (503.16388240000003)
(2s)-5-hydroxy-1-[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid
C24H25NO11 (503.14275399999997)
(1'r,2r,9r,9as,12'r)-2-benzyl-15'-hydroxy-12'-methyl-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
[8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-yl]oxidanesulfonic acid
C26H21N3O6S (503.11510060000006)
7-(2-{2-[4-(3-isopropyloxiran-2-yl)but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)
(2e,4r,5s,6e)-7-(2-{2-[(2s,3e)-4-(3-isopropyloxiran-2-yl)but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)
[(1e)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid
[(1z)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid
2-(3-hydroxy-4-methoxyphenyl)-2-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}acetonitrile
C21H29NO13 (503.16388240000003)
2-benzyl-15'-hydroxy-12'-methyl-2,9a-dihydro-1h-2',10',16'-triazaspiro[imidazo[1,2-a]indole-9,13'-tetracyclo[10.2.2.0²,¹¹.0⁴,⁹]hexadecane]-4',6',8',10',15'-pentaene-3,3'-dione
5-hydroxy-1-[3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid
C24H25NO11 (503.14275399999997)
(2e,4r,5s,6e)-7-(2-{2-[(2s,3e)-4-[(2s,3r)-3-isopropyloxiran-2-yl]but-3-en-2-yl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)-3,5-dimethoxy-4-methylhepta-2,6-dienimidic acid
C25H33N3O4S2 (503.19123780000007)